



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

depended on their vote at the first round of the 2017 presidential election (figure): those who had voted for a far left or far right candidate were much more likely to state that they would refuse the vaccine, as well as those who abstained from voting.

These early results are not entirely surprising. When this dimension has been studied, researchers have often found a connection between political beliefs and attitudes to vaccines.⁶ They highlight a crucial issue for public health interventions: how can we assure the public that recommendations reflect the state of scientific knowledge rather than political interests? This problem is exacerbated in times of crisis, during which there is considerable scientific uncertainty, available measures have a limited effect, and politicians—rather than experts—are the public face of crisis management. This is one of the lessons that can be drawn from the H1N1 influenza pandemic of 2009 in France. As the pandemic unfolded, the apparent national unity of the early phase broke apart. Criticism of the government's strategy was voiced by prominent members of nearly all of the opposition parties.⁷ A public debate around the safety of the vaccine arose, with prominent politicians and activists claiming that it had been produced too hastily and not been tested enough. This was crucial in the failure of the vaccination campaign (only 8% of the population was vaccinated).⁸ It also ushered in an era of perpetual debate over vaccination in France.⁹ One of the crucial mistakes made at the time by French authorities was to refuse to communicate early on the measures taken to ensure the safety of the vaccine for fear that the mere evocation of risk might provoke irrational reactions.¹⁰ This approach let critics set the agenda on this issue, condemning public authorities to a defensive position.

Public authorities are setting up fast-track approval processes for a putative vaccine against SARS-CoV-2.⁹ It is crucial to communicate early and transparently on these processes to avoid vaccines becoming part of political debates.

We declare no competing interests.

The COCONEL Group
patrick.peretti-watel@inserm.fr

The COCONEL Group includes: Patrick Peretti-Watel (scientific coordinator), Valérie Seror, Sébastien Cortaredona, Odile Launay, Jocelyn Raude, Pierre Verger (research consortium), François Beck, Stéphane Legleye, Olivier L'Haridon, Jeremy Ward (steering committee)

Aix Marseille Université, IRD, AP-HM, SSA, VITROME, Marseille, France (PP-W, VS, SC, JW); Southeastern Health Regional Observatory (ORS Paca), Marseille, France (PP-W, PV); Inserm CIC 1417, Université Paris, Faculté de Médecine Paris Descartes, AP-HP, Hôpital Cochin, Paris, France (OL); EHESP School of Public Health, Rennes, France (JR); CESP, Université Paris Sud, Faculté de Médecine UVSQ, Inserm, Université Paris-Saclay, Villejuif, France (FB, SL); Université Rennes, CNRS, CREM UMR 6211, Rennes, France (OL'H); and GEMASS, CNRS, Université Paris Sorbonne, Paris, France (JW)

- 1 Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK. Ensuring global access to COVID-19 vaccines. *Lancet* 2020; **395**: 1405–06.
- 2 Shetty P. Experts concerned about vaccination backlash. *Lancet* 2010; **375**: 970–71.
- 3 Larson HJ, de Figueiredo A, Xiaohong Z, et al. The state of vaccine confidence 2016: global insights through a 67-country survey. *EBioMedicine* 2016; **12**: 295–301.
- 4 Maertens de Noordhout C, Devleesschauwer B, Salomon JA, et al. Disability weights for infectious diseases in four European countries: comparison between countries and across respondent characteristics. *Eur J Public Health* 2018; **28**: 124–33.
- 5 Peretti-Watel P, Ward JK, Vergelys C, Bocquier A, Raude J, Verger P. 'I think I made the right decision ... I hope I'm not wrong'. Vaccine hesitancy, commitment and trust among parents of young children. *Social Health Illn* 2019; **41**: 1192–206.
- 6 Kennedy J. Populist politics and vaccine hesitancy in Western Europe: an analysis of national-level data. *Eur J Public Health* 2019; **29**: 512–16.
- 7 Ward JK. Rethinking the antivaccine movement concept: a case study of public criticism of the swine flu vaccine's safety in France. *Soc Sci Med* 2016; **159**: 48–57.
- 8 Raude J, Caille-Brillet A-L, Setbon M. The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the vaccine and why? *PLoS Curr* 2010; **2**: RRN1188.
- 9 Ward JK, Peretti-Watel P, Bocquier A, Seror V, Verger P. Vaccine hesitancy and coercion: all eyes on France. *Nat Immunol* 2019; **20**: 1257–59.
- 10 Ward JK. Informer sans inquiéter: rationalité et irrationalité du public dans la communication sur la grippe A. In: Les publics de l'action publique: gouvernement et résistances. Villeneuve-d'Ascq: Presses du Septentrion, 2016.



Global outbreak research: harmony not hegemony

Published Online
June 2, 2020

[https://doi.org/10.1016/S1473-3099\(20\)30440-0](https://doi.org/10.1016/S1473-3099(20)30440-0)

To make clinical and biological observations within a timeframe that is likely to benefit patients during disease outbreaks, coordination of global research must match the speed of spread of novel pathogens. Time is short. Circumstances call for international collaboration to understand, treat, and prevent coronavirus disease 2019 (COVID-19).

During previous infectious disease outbreaks, clinical research has often been established on an ad-hoc basis and done in silos, using different methodologies and designs. This approach limits opportunities to compare results, or to combine smaller studies to obtain answers quickly. Thus, perhaps it is self-evident that harmonisation of clinical investigation during

outbreaks is desirable. In a meeting of the WHO clinical management research prioritisation group held in January, 2020, harmonised clinical characterisation research was identified as the first priority for COVID-19.

Harmonisation creates opportunities for individual investigators to compare results or collaborate, without applying burdens or obligations. In our experience, the quality and breadth of research is improved by collaborative development and peer review of shared protocols. For example, in the current outbreak, a clinician might design a study to identify risk factors for progression, co-infections, and mechanisms of critical illness. However, clinicians might overlook the need to obtain serum for research groups with the capability to make new assays for seroepidemiology, or peripheral blood mononuclear cells for monoclonal antibody therapeutics during this process. Wide collaboration leads to better, faster science.

Achieving global coordination is difficult enough at the best of times; during a crisis it might seem impossible. But with each new crisis, the same questions arise again and again, and so, the same designs can be used to tackle them. We believe that global harmonisation is possible, at least in the intermittently indispensable field of outbreak research. To achieve such a goal, harmonised investigation needs to be made easier than establishing isolated independent studies, must respect autonomy and sovereignty of investigators, and relinquish normal routes of academic recognition for this work.

To this end, in 2012, a single, standardised generic research protocol was created for clinical characterisation of any emerging infection (the International Severe Acute Respiratory and Emerging Infection Consortium [ISARIC]/WHO Clinical Characterisation Protocol [CCP]), which was the result of many years of international and cross-speciality consensus-building.¹ Since the fundamental research questions in a new outbreak are predictable, the protocol can be established and approved in so-called peacetime, maintained in a hibernating state, then rapidly implemented when required. Carefully designed, flexible biological sampling schedules are included in tiers according to local resources, modular additional studies for specific situations, and scalable case report forms.¹ These tools were released under an open-source licence—ie, anyone can download these materials and use, adapt, or distribute them. Clinical research can

feel like it is 95% about filling in forms. We filled in some of the forms, so you don't have to.

In 2016, the ISARIC/WHO CCP was implemented in Brazil in response to the emergence of Zika virus and chikungunya virus in Latin America, facilitating studies of viral shedding and serology.² The CCP was also used for the establishment of cohort studies of critically ill patients with Middle East respiratory syndrome.³ At present, the Uganda Virus Research Institute (Entebbe, Uganda) is using the protocol to study severe acute febrile illness and severe influenza.⁴ The value of this approach is becoming apparent in the age of COVID-19. The original reports on clinical findings in COVID-19 used harmonised data collection.^{5,6} 46 countries have registered to record clinical data using the ISARIC/WHO CCP Case Report Form and investigators in many countries are planning to use the CCP biological sampling protocol to coordinate studies of transmission, prognostication, pathogenesis, and diagnostics (appendix).

See Online for appendix

Understanding the genetic mechanisms underlying susceptibility⁷ might directly advance our understanding of disease mechanisms⁸ and possible treatments,⁹ but robust studies require recruitment of large numbers of critically ill patients, which requires open, collegiate, and global collaboration. Genetics Of Mortality In Critical Care is an open consortium in which clinicians have been recruiting critically ill patients since 2016. Importantly, this work is led by the clinicians treating the patients, in collaboration with experts in host genetics.

For more on GenOMICC see <https://genomicc.org>

Operating clinical trials at global scale presents many additional challenges, but even in this domain, substantial progress has been made. Before the COVID-19 pandemic, the critical care community created a highly efficient, randomised, embedded multifactorial adaptive platform trial for community-acquired pneumonia (REMAP-CAP). This single trial was established in 13 countries with the capacity to test new hypotheses quickly. Perhaps most ambitious of all, WHO has developed a global platform—the SOLIDARITY trial¹⁰—for the evaluation of widely-available interventions to treat COVID-19.

For more on the ISARIC/WHO CCP see <https://isaric.net/ccp/>

For more on REMAP-CAP see <https://www.remcap.org>

Catastrophes, such as pandemics, drive innovation and lead to marked social change. Within the scientific research community, we believe that perceptions of academic excellence have long undervalued teamwork and collegiality. We hope our colleagues across the world

will make use of these tools, either in collaboration or independently, to harmonise clinical research efforts and fulfil the duties of medical science to humanity in the shortest time possible.

We declare no competing interests.

ISARIC clinical characterisation group

clarkdrussell@gmail.com; j.k.baillie@ed.ac.uk

Roslin Institute, University of Edinburgh, Edinburgh EH25 9RG, UK

- 1 Dunning JW, Merson L, Rohde GGU, et al. Open source clinical science for emerging infections. *Lancet Infect Dis* 2014; **14**: 8–9.
- 2 Bozza FA, Moreira-Soto A, Rockstroh A, et al. Differential shedding and antibody kinetics of zika and chikungunya viruses, Brazil. *Emerg Infect Dis* 2019; **25**: 311–15.
- 3 Arabi YM, Al-Omari A, Mandourah Y, et al. Critically ill patients with the middle east respiratory syndrome: A multicenter retrospective cohort study. *Crit Care Med* 2017; **45**: 1683–95.
- 4 Cummings MJ, Bakamutumaho B, Kayiwa J, et al. Epidemiologic and spatiotemporal characterization of influenza and severe acute respiratory infection in Uganda, 2010–2015. *Ann Am Thorac Soc* 2016; **13**: 2159–68.
- 5 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497–506.
- 6 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; published online Feb 24. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5).
- 7 Patačić I, Gelemanović A, Kirin M, et al. The role of host genetic factors in respiratory tract infectious diseases: systematic review, meta-analyses and field synopsis. *Sci Rep* 2015; **5**: 16119.
- 8 Russell CD, Baillie JK. Treatable traits and therapeutic targets: goals for systems biology in infectious disease. *Curr Opin Syst Biol* 2017; **2**: 139–45.
- 9 Baillie JK. Translational genomics. Targeting the host immune response to fight infection. *Science* 2014; **344**: 807–08.
- 10 WHO. “Solidarity” clinical trial for COVID-19 treatments. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> (accessed May 5, 2020).